Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Scandinavian Journal of Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9669637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease?

  1997cited by this paper
• No evidence of activated blood coagulation in Crohn's disease

  1997cited by this paper
• Inherited disorders of coagulation appear to protect against inflammatory bowel disease.

  1995cited by this paper
• Prothrombin fragment 1+2 and thrombin–antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases

  1995cited by this paper
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

  1995cited by this paper
• Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease

  1995cited by this paper
• Fibrinolytic split products, fibrinolysis, and factor XIII activity in inflammatory bowel disease.

  1995cited by this paper
• Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.

  1994cited by this paper
• Inflammatory mediators and their influence on haemostasis.

  1994cited by this paper
• Correlation between clotting and collagen metabolism markers in rheumatoid arthritis.

  1994cited by this paper
• Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees

  1994cited by this paper
• Influence of conditions of blood sampling on coagulation activation markers (prothrombin fragment 1 + 2, thrombin-antithrombin complexes and D-dimers) measurements.

  1994cited by this paper
• Assessment of disease severity and activity in inflammatory bowel disease.

  1993cited by this paper
• Laboratory markers of coagulation activation.

  1993cited by this paper
• Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases

  1993cited by this paper
• Evidence for activation of coagulation in Crohn's disease

  1992cited by this paper
• Detection of the prethrombotic state due to procoagulant imbalance

  1992cited by this paper
• Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements.

  1991cited by this paper
• Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis.

  1991cited by this paper
• Granulomatous vasculitis in Crohn's disease.

  1991cited by this paper
• Assessment of hypercoagulable states by measurement of activation fragments and peptides.

  1990cited by this paper
• Platelet Count, Platelet Function, Coagulation Activity and Fibrinolysis in the Acute Phase of Inflammatory Bowel Disease

  1990cited by this paper
• Activation of coagulation after administration of tumor necrosis factor to normal subjects.

  1990cited by this paper
• Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

  1989cited by this paper
• Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

  1989cited by this paper
• Prothrombotic abnormalities in inflammatory bowel disease

  1989cited by this paper
• Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

  1989cited by this paper
• The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study.

  1988cited by this paper
• IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease.

  1987cited by this paper
• Vascular complications of inflammatory bowel disease.

  1986cited by this paper
• European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

  1984cited by this paper
• Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis

  1982cited by this paper
• Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978.

  1982cited by this paper
• A simple index of Crohn's-disease activity.

  1980cited by this paper
• Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management.

  1979cited by this paper

• Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease

  2025cites this paper
• The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review

  2022cites this paper
• Altered functional responses by PAR1 agonist in murine dextran sodium sulphate-treated colon

  2022cites this paper
• Impact of Obesity on Inflammatory Bowel Disease

  2022cites this paper
• Safety of Venous Thromboprophylaxis With Low-molecular-weight Heparin in Children With Ulcerative Colitis

  2021cites this paper
• Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management

  2021cites this paper
• Experimental and clinical evidence of endothelial dysfunction in inflammatory bowel disease.

  2020cites this paper
• Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.

  2020cites this paper
• Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study.

  2020cites this paper
• The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study

  2018cites this paper
• Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease

  2017cites this paper
• Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease

  2017cites this paper
• Thrombosis in the setting of obesity or inflammatory bowel disease.

  2016cites this paper
• Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.

  2016cites this paper
• Thrombosis in the setting of obesity or inflammatory bowel disease.

  2016cites this paper
• Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

  2012cites this paper
• Inflammatory Bowel Disease and Thrombosis

  2012cites this paper
• Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease

  2011cites this paper
• Coagulation and inflammation

  2011cites this paper
• Systematic review on the effect of glucocorticoid use on procoagulant, anti‐coagulant and fibrinolytic factors

  2010cites this paper
• Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.

  2009cites this paper
• Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis.

  2009cites this paper
• Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis.

  2007cites this paper
• Low‐molecular‐weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study

  2006cites this paper
• Disseminated intravascular coagulation in an ambulatory young woman.

  2005cites this paper
• Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation.

  2005cites this paper
• Mast Cell Tryptase Controls Paracellular Permeability of the Intestine

  2005cites this paper
• Assessment of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels in Inflammatory Bowel Diseases

  2004cites this paper
• Severe ulcerative colitis: Prospective study of parameters determining outcome

  2004cites this paper
• A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

  2004cites this paper
• The 4G/4G genotype of the 4G/5G polymorphism of the type‐1 plasminogen activator inhibitor (PAI‐1) gene is a determinant of penetrating behaviour in patients with Crohn's disease

  2003cites this paper
• Haemostasis in inflammatory bowel diseases: clinical relevance.

  2003cites this paper
• Coagulation and Fibrinolysis in Inflammatory Bowel Disease and in Giant Cell Arteritis

  2003cites this paper
• Immune thrombocytopenic purpura in patients with ulcerative colitis

  2003cites this paper
• Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel Disease

  2002cites this paper
• Hyperhomocysteinaemia, Coagulation Pathway Activation and Thrombophilia in Patients with Inflammatory Bowel Disease

  2002cites this paper
• Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis

  2002cites this paper
• Lipoprotein (a), thrombophilia and inflammatory bowel disease

  2001cites this paper
• Hemostatic imbalance in active and quiescent ulcerative colitis

  2001cites this paper
• Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease

  2001cites this paper
• Diagnostic markers of inflammatory bowel disease

  2000cites this paper
• Inflammatory Bowel Disease Promotes Venous Thrombosis Earlier in Life

  2000cites this paper
• Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study

  1999cites this paper
• Heparin and inflammatory bowel disease.

  1999cites this paper